CHEMIOTERAPIA CON FUDR IN INFUSIONE CONTINUA NEL TRATTAMENTO DEL CARCINOMA RENALE METASTATICO O IN STADIO AVANZATO

Translated title of the contribution: Continuous infusion chemotherapy with FUDR in the treatment of advanced metastatic renal carcinoma

A. Del Nero, A. Mandressi, G. Zanetti, A. Trinchieri, E. Patelli, G. L. Taverna, E. Austoni

Research output: Contribution to journalArticle

Abstract

The cases of metastatic renal cell carcinoma and 14 cases of advanced renal cell carcinoma were treated with continuous circadian venous infusion of 5-Fluoro 2-Deoxyuridine (FUDR). The drug was delivered by a Medtronic Synchromed implantable pump in 14 day cycles alternating within 14 day intervals of physiologic saline infusion. Of the patients observed for at least 18 months (range: 18-46 months, median: 32.4) in Group A, 5 showed progress, 3 stable disease (range: 9-20 months), 2 partial response (range: 9-29 months), while in Group B, only 1 case showed progression. Continuous circadian central venous infusion of FUDR is minimally toxic. FUDR may be delivered safely and conveniently in this way for long spans. Therapy is administered entirely in an out-patient setting, and associated with a normal quality of life.

Original languageItalian
Pages (from-to)83-84
Number of pages2
JournalActa Urologica Italica
Volume6
Issue numberSUPPL. 4
Publication statusPublished - 1992

Fingerprint

Deoxyuridine
Renal Cell Carcinoma
Carcinoma
Kidney
Drug Therapy
Poisons
Outpatients
Quality of Life
Therapeutics
Pharmaceutical Preparations
5-fluoro-2'-deoxyuridine

ASJC Scopus subject areas

  • Urology

Cite this

Del Nero, A., Mandressi, A., Zanetti, G., Trinchieri, A., Patelli, E., Taverna, G. L., & Austoni, E. (1992). CHEMIOTERAPIA CON FUDR IN INFUSIONE CONTINUA NEL TRATTAMENTO DEL CARCINOMA RENALE METASTATICO O IN STADIO AVANZATO. Acta Urologica Italica, 6(SUPPL. 4), 83-84.

CHEMIOTERAPIA CON FUDR IN INFUSIONE CONTINUA NEL TRATTAMENTO DEL CARCINOMA RENALE METASTATICO O IN STADIO AVANZATO. / Del Nero, A.; Mandressi, A.; Zanetti, G.; Trinchieri, A.; Patelli, E.; Taverna, G. L.; Austoni, E.

In: Acta Urologica Italica, Vol. 6, No. SUPPL. 4, 1992, p. 83-84.

Research output: Contribution to journalArticle

Del Nero, A, Mandressi, A, Zanetti, G, Trinchieri, A, Patelli, E, Taverna, GL & Austoni, E 1992, 'CHEMIOTERAPIA CON FUDR IN INFUSIONE CONTINUA NEL TRATTAMENTO DEL CARCINOMA RENALE METASTATICO O IN STADIO AVANZATO', Acta Urologica Italica, vol. 6, no. SUPPL. 4, pp. 83-84.
Del Nero, A. ; Mandressi, A. ; Zanetti, G. ; Trinchieri, A. ; Patelli, E. ; Taverna, G. L. ; Austoni, E. / CHEMIOTERAPIA CON FUDR IN INFUSIONE CONTINUA NEL TRATTAMENTO DEL CARCINOMA RENALE METASTATICO O IN STADIO AVANZATO. In: Acta Urologica Italica. 1992 ; Vol. 6, No. SUPPL. 4. pp. 83-84.
@article{a7a0824c9f2d4326af52566d0d8f8582,
title = "CHEMIOTERAPIA CON FUDR IN INFUSIONE CONTINUA NEL TRATTAMENTO DEL CARCINOMA RENALE METASTATICO O IN STADIO AVANZATO",
abstract = "The cases of metastatic renal cell carcinoma and 14 cases of advanced renal cell carcinoma were treated with continuous circadian venous infusion of 5-Fluoro 2-Deoxyuridine (FUDR). The drug was delivered by a Medtronic Synchromed implantable pump in 14 day cycles alternating within 14 day intervals of physiologic saline infusion. Of the patients observed for at least 18 months (range: 18-46 months, median: 32.4) in Group A, 5 showed progress, 3 stable disease (range: 9-20 months), 2 partial response (range: 9-29 months), while in Group B, only 1 case showed progression. Continuous circadian central venous infusion of FUDR is minimally toxic. FUDR may be delivered safely and conveniently in this way for long spans. Therapy is administered entirely in an out-patient setting, and associated with a normal quality of life.",
author = "{Del Nero}, A. and A. Mandressi and G. Zanetti and A. Trinchieri and E. Patelli and Taverna, {G. L.} and E. Austoni",
year = "1992",
language = "Italian",
volume = "6",
pages = "83--84",
journal = "Acta Urologica Italica",
issn = "0394-2511",
publisher = "S. Karger AG",
number = "SUPPL. 4",

}

TY - JOUR

T1 - CHEMIOTERAPIA CON FUDR IN INFUSIONE CONTINUA NEL TRATTAMENTO DEL CARCINOMA RENALE METASTATICO O IN STADIO AVANZATO

AU - Del Nero, A.

AU - Mandressi, A.

AU - Zanetti, G.

AU - Trinchieri, A.

AU - Patelli, E.

AU - Taverna, G. L.

AU - Austoni, E.

PY - 1992

Y1 - 1992

N2 - The cases of metastatic renal cell carcinoma and 14 cases of advanced renal cell carcinoma were treated with continuous circadian venous infusion of 5-Fluoro 2-Deoxyuridine (FUDR). The drug was delivered by a Medtronic Synchromed implantable pump in 14 day cycles alternating within 14 day intervals of physiologic saline infusion. Of the patients observed for at least 18 months (range: 18-46 months, median: 32.4) in Group A, 5 showed progress, 3 stable disease (range: 9-20 months), 2 partial response (range: 9-29 months), while in Group B, only 1 case showed progression. Continuous circadian central venous infusion of FUDR is minimally toxic. FUDR may be delivered safely and conveniently in this way for long spans. Therapy is administered entirely in an out-patient setting, and associated with a normal quality of life.

AB - The cases of metastatic renal cell carcinoma and 14 cases of advanced renal cell carcinoma were treated with continuous circadian venous infusion of 5-Fluoro 2-Deoxyuridine (FUDR). The drug was delivered by a Medtronic Synchromed implantable pump in 14 day cycles alternating within 14 day intervals of physiologic saline infusion. Of the patients observed for at least 18 months (range: 18-46 months, median: 32.4) in Group A, 5 showed progress, 3 stable disease (range: 9-20 months), 2 partial response (range: 9-29 months), while in Group B, only 1 case showed progression. Continuous circadian central venous infusion of FUDR is minimally toxic. FUDR may be delivered safely and conveniently in this way for long spans. Therapy is administered entirely in an out-patient setting, and associated with a normal quality of life.

UR - http://www.scopus.com/inward/record.url?scp=0026714454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026714454&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0026714454

VL - 6

SP - 83

EP - 84

JO - Acta Urologica Italica

JF - Acta Urologica Italica

SN - 0394-2511

IS - SUPPL. 4

ER -